Evidence map›Paper›PMID 33190426›Full record

ArticleBiotechnology progress2021

Effects of variable domain orientation on anti-HER2 single-chain variable fragment antibody expressed in the Escherichia coli cytoplasm.

İlkay Koçer, Emily C Cox, Matthew P DeLisa, Eda Çelik

Open access · greenAbstract read
In one paragraph

Article in Biotechnology progress, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Escherichia coli in the production of biopharmaceuticals.Biotechnology and applied biochemistry · 2025
    Review
  6. Article
  7. Article
  8. Ribosome Stalling ofACS synthetic biology · 2022
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

İlkay KoçerDepartment of Chemical Engineering, Hacettepe University, Ankara, Turkey.ORCID 0000-0002-5299-4567
Emily C CoxBiological and Biomedical Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York, USA.
Matthew P DeLisaRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA.ORCID 0000-0003-3226-1566
Eda ÇelikDepartment of Chemical Engineering, Hacettepe University, Ankara, Turkey.ORCID 0000-0003-3203-2181
Cornell University · USHacettepe University · TR

Funding

Molecular toolkit for high content resolution of glycomes by expansionmicroscopyR01GM137314 · NIGMS · CORNELL UNIVERSITY · PI ALABI, CHRISTOPHER AKINLEYE, DELISA, MATTHEW P · 2020 to 2023
$1.8M
Technologies to predict and probe glycosyl transferR01GM127578 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GRAY, JEFFREY J · 2018 to 2020
$1.6M
Defense Threat Reduction Agency HDTRA1-20-10004National Science Foundation 1605242NIGMS NIH HHS R01 GM127578NIGMS NIH HHS R01 GM137314Türkiye Bilimsel ve Teknolojik Araştirma Kurumu 2214-A
6 · The paper itself

Abstract

Single-chain variable fragment (scFv) antibodies have great potential for a range of applications including as diagnostic and therapeutic agents. However, production of scFvs is challenging because proper folding and activity depend on the formation of two intrachain disulfide bonds that do not readily form in the cytoplasm of living cells. Functional expression in bacteria therefore involves targeting to the more oxidizing periplasm, but yields in this compartment can be limiting due to secretion bottlenecks and the relatively small volume compared to the cytoplasm. In the present study, we evaluated an anti-HER2 scFv, which is specific for human epidermal growth receptor 2 (HER2) overexpressed in breast cancer, for functional expression in the cytoplasm of Escherichia coli strains BL21(DE3) and SHuffle T7 Express, the latter of which is genetically engineered for cytoplasmic disulfide bond formation. Specifically, we observed much greater solubility and binding activity with SHuffle T7 Express cells, which likely resulted from the more oxidative cytoplasm in this strain background. We also found that SHuffle T7 Express cells were capable of supporting high-level soluble production of anti-HER2 scFvs with intact disulfide bonds independent of variable domain orientation, providing further evidence that SHuffle T7 Express is a promising host for laboratory and preparative expression of functional scFv antibodies.

Indexed as

Breast NeoplasmsCytoplasmErb-b2 Receptor Tyrosine KinasesEscherichia coliFemaleHumansSingle-Chain AntibodiesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesSingle-Chain Antibodiesanti-HER2cytoplasmic expressionscFvVL/VH orientation

Identifiers

PMID33190426
PMCPMC8842847
OpenAlexW3102821416

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.